MAPT and Alzheimer disease: In our cohort, we found that among A + T − patients, CSFAβ42 + /amyR + showed a higher probability of having pathological levels of p-tau/Aβ42, a well-known marker of AD-related burden, than CSFAβ42 + /amyR − .